Literature DB >> 10432389

Renal actions of synthetic dendroaspis natriuretic peptide.

O Lisy1, M Jougasaki, D M Heublein, J A Schirger, H H Chen, P W Wennberg, J C Burnett.   

Abstract

BACKGROUND: Dendroaspis natriuretic peptide (DNP), recently isolated from the venom of the green Mamba snake Dendroaspis angusticeps, is a 38 amino acid peptide containing a 17 amino acid disulfide ring structure similar to that of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP). DNP-like immunoreactivity (DNP-LI) was reported to be present in human plasma and atrial myocardium and to be elevated in human congestive heart failure. Although previously named DNP, it remains unknown if DNP is natriuretic or if is it present in canine plasma, urine, and atrial myocardium.
METHOD: Studies were performed in vivo in anesthetized dogs (N = 6) using intravenous infusion of synthetic DNP at 10 and 50 ng/kg/min. Employing a sensitive and specific radioimmunoassay for DNP, the presence of DNP-like peptide was assessed in the canine plasma and urine before, during, and following the administration of exogenous synthetic DNP. Additionally, we performed immunohistochemical studies using the indirect immunoperoxidase method with polyclonal DNP antiserum in normal atrial myocardium (N = 10). Atrial concentrations of DNP-LI were also assessed.
RESULTS: We report that DNP is markedly natriuretic and diuretic, which, like ANP and BNP, is associated with the increase in urinary and plasma cGMP. DNP-like peptide is also detected in canine plasma, urine, and atrial myocardium.
CONCLUSION: These studies establish that DNP is a potent natriuretic and diuretic peptide with tubular actions linked to cGMP and that DNP may play a physiological role in the regulation of sodium excretion.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10432389     DOI: 10.1046/j.1523-1755.1999.00573.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  26 in total

Review 1.  Novel natriuretic peptides: new compounds and new approaches.

Authors:  Mark W Vogel; Horng H Chen
Journal:  Curr Heart Fail Rep       Date:  2011-03

Review 2.  Cyclic nucleotide regulation of cardiac sympatho-vagal responsiveness.

Authors:  Dan Li; David J Paterson
Journal:  J Physiol       Date:  2016-05-05       Impact factor: 5.182

3.  Dendroaspis natriuretic peptide relaxes gastric antral circular smooth muscle of guinea-pig through the cGMP/cGMP-dependent protein kinase pathway.

Authors:  Chun-Yu Cai; Zheng-Xu Cai; Xin-Yi Gu; Lu-Juan Shan; Yong-Xiao Wang; Xue-Zhe Yin; Qing-Hui Qi; Hui-Shu Guo
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

Review 4.  Privileged frameworks from snake venom.

Authors:  T A Reeks; B G Fry; P F Alewood
Journal:  Cell Mol Life Sci       Date:  2015-02-19       Impact factor: 9.261

5.  Characterization of the snake venom ligand [125I]-DNP binding to natriuretic peptide receptor-A in human artery and potent DNP mediated vasodilatation.

Authors:  G Singh; J J Maguire; R E Kuc; J N Skepper; M Fidock; A P Davenport
Journal:  Br J Pharmacol       Date:  2006-10-16       Impact factor: 8.739

Review 6.  Natriuretic peptide based therapeutics for heart failure: Cenderitide: A novel first-in-class designer natriuretic peptide.

Authors:  Tomoko Ichiki; Nina Dzhoyashvili; John C Burnett
Journal:  Int J Cardiol       Date:  2018-06-03       Impact factor: 4.164

Review 7.  Novel vasodilators in heart failure.

Authors:  Payman Zamani; Barry H Greenberg
Journal:  Curr Heart Fail Rep       Date:  2013-03

8.  Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP.

Authors:  Ondrej Lisy; Brenda K Huntley; Daniel J McCormick; Paul A Kurlansky; John C Burnett
Journal:  J Am Coll Cardiol       Date:  2008-07-01       Impact factor: 24.094

Review 9.  B-type natriuretic peptide: beyond a diagnostic.

Authors:  Fernando L Martin; Horng H Chen; Alessandro Cataliotti; John C Burnett
Journal:  Heart Fail Clin       Date:  2008-10       Impact factor: 3.179

Review 10.  Modulation of cGMP in heart failure: a new therapeutic paradigm.

Authors:  Guido Boerrigter; Harald Lapp; John C Burnett
Journal:  Handb Exp Pharmacol       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.